ERIBULIN MESYLATE INJECTION DIN 02560399
Health Canada record
| Active ingredient(s) | ERIBULIN MESYLATE 0.5 MG |
|---|---|
| Dosage form | Solution |
| Route | Intravenous |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | L01XX41 ERIBULIN |
| Original market date | |
| Current status date | 10-Oct-2025 |
| Source | Health Canada DPD |
Establishment licence of the holder
Baxter Corporation — licence 100278, currently licensed, last inspection rating C (2026-08-11).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing ERIBULIN MESYLATE
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02545950 | ERIBULIN MESYLATE INJECTION | DR REDDY'S LABORATORIES LTD | Solution | ERIBULIN MESYLATE 0.5 MG | Marketed |
| 02564467 | ERIBULIN MESYLATE INJECTION | MARCAN PHARMACEUTICALS INC | Solution | ERIBULIN MESYLATE 0.5 MG | Approved |
| 02377438 | HALAVEN | EISAI LIMITED | Solution | ERIBULIN MESYLATE 0.5 MG | Marketed |
| 02539136 | NAT-ERIBULIN | NATCO PHARMA (CANADA) INC | Solution | ERIBULIN MESYLATE 0.5 MG | Dormant |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 36152 | 2025-10-10 | Abbreviated New Drug Submission (ANDS) |
International API supply for ERIBULIN MESYLATE
14 active FDA Drug Master Files.
Request a quote for ERIBULIN MESYLATE INJECTION